[npj Cardiovascular Health] Researchers presented a temporal map of organotypic changes in endothelial proliferation at different stages of mouse life. Comparative analyses of 12 different organs revealed a tissue-specific pattern of age-related changes in endothelial proliferation capacity.
[Microsystems & Nanoengineering] The authors introduce an etiology-to-model framework that maps six principal classes of vascular disease, including congenital, metabolic, neoplastic, inflammatory, degenerative, and risk factor-induced, to the in vitro systems best equipped to reproduce their defining microenvironmental disturbances.
[Texas Children’s ] Dr. Rui Yang has been awarded the Burroughs Wellcome Fund Career Award for Medical Scientists. Yang’s research focuses on understanding the genetics of immune reactions that underlie severe infectious and autoimmune diseases and working to identify how inherited variations in immune system pathways contribute to susceptibility to infection and immune dysfunction.
[Mount Sinai Today Blog] A gift from philanthropists Judith and Stewart Colton will establish a Colton Center for Autoimmunity within the Marc and Jennifer Lipschultz Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai. This move expands research focused on earlier detection, precision treatment, and disease prevention.
[Nature Medicine] This Phase I/II trial evaluated an investigational maternal hexavalent polysaccharide−protein conjugate GBS vaccine in non-pregnant females and pregnant participants and their infants.
[Science] Investigators constructed a single-cell 3D genome atlas of human tonsil cells and characterized changes in multiscale 3D genome features during germinal center B cell development.
[Nature Reviews Gastroenterology & Hepatology] Expanding preclinical and clinical literature from PDAC and other oncological indications identifies novel approaches through which radiation therapy–immunotherapy combinations could improve local and systemic disease control in patients with PDAC.
[US FDA] The US FDA approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.